Publication: Dataset for Reporting of Malignant Mesothelioma of the Pleura or Peritoneum: Recommendations From the International Collaboration on Cancer Reporting (ICCR)
No Thumbnail Available
Open/View Files
Date
2016-10
Published Version
Journal Title
Journal ISSN
Volume Title
Publisher
Archives of Pathology and Laboratory Medicine
The Harvard community has made this article openly available. Please share how this access benefits you.
Citation
Andrew Churg, Richard Attanoos, Alain C. Borczuk, Lucian R. Chirieac, Françoise Galateau-Sallé, Allen Gibbs, Douglas Henderson, Victor Roggli, Valerie Rusch, Meagan J. Judge, and John R. Srigley (2016) Dataset for Reporting of Malignant Mesothelioma of the Pleura or Peritoneum: Recommendations From the International Collaboration on Cancer Reporting (ICCR). Archives of Pathology & Laboratory Medicine: October 2016, Vol. 140, No. 10, pp. 1104-1110.
Research Data
Abstract
Context
The International Collaboration on Cancer Reporting (ICCR) is a not-for-profit organisation formed by the Royal Colleges of Pathologists of Australasia and the United Kingdom, the College of American Pathologists, the Canadian Association of Pathologists-Association Canadienne des Pathologists (CAP-ACP) in association with the Canadian Partnership Against Cancer (CPAC), and the European Society of Pathology (ESP). Its goal is to produce common, internationally agreed, evidence-based datasets for use throughout the world.
Objective and Design
This paper describes a dataset developed by the ICCR expert panel for the reporting of malignant mesothelioma of both the pleura and peritoneum. The dataset is composed of elements ‘required’ (mandatory) and ‘recommended’ (non-mandatory), which are based on a review of the most recent evidence and supported by explanatory commentary.
Results
Eight required elements and seven recommended elements were agreed by the expert panel to represent the essential information for the reporting of malignant mesothelioma of the pleura and peritoneum.
Conclusions
In time, the widespread utilisation of an internationally agreed, structured pathology dataset for mesothelioma will lead not only to improved patient management but provide valuable data for research and international benchmarking.
Description
Other Available Sources
Keywords
Terms of Use
This article is made available under the terms and conditions applicable to Open Access Policy Articles (OAP), as set forth at Terms of Service